Company intelligence / Profile preview

Acurex Biosciences

San Carlos, California, United States

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Early clinical results support the use of novel blood-based biomarkers for early detection and monitoring of Parkinson’s disease pathology. Lead therapeutic candidate CU-13001 is advancing toward IND filing with strong preclinical efficacy data in models of PD.

Therapeutic areas: Neurology
Modalities: Small moleculesBiomarkers (diagnostic tools)
Industry: Biotech

Drug pipeline

3 assets

CU-13001

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Michael J. Fox Foundation for Parkinson’s ResearchStanford University, University of California, The Silverstein Foundation, National Institute on AgingParkinson’s UK – £1.59m investment through Virtual Biotech programme to advance CU‑13001 into clinical trials

Beyond the preview

Go deeper on Acurex Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acurex Biosciences.

Explore the full profile